Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
AVXL and MGTI my best specs for possible enormous growth. AVXL my top pick.
According to Steve Schaeffer 3 minining locations now in Washington State, and goal is to become largest miner in N. America, probably includes Ethereum too imo. This guy has big equity fund experience and mining experience as well. Already showing us investors he will keep us informed on company milestones more than JM did.
When PD preclinical tests are released from Lund University in Sweden, if they show anything positive, imo we go to $20. Trials may start way before we investors hear the results as has the Rett trials recruitment.
$5 Tomorrow if all today's posters just bought 1000 shares tomorrow. MS news, PD news, Rett news and AD news all within weeks away at these upcoming conferences, Sept. Oct. Nov !
PK/PD Data must be available. All 3 trials were not to begin without that information. Sounds positive to Me !
Sept 11th CNS Conference: ANAVEX 2-73, a Sigma-1 Receptor Agonist, Targeting Neurodegenerative and Neurodevelopmental Diseases
Daniel Klamer Daniel Klamer
Vice President, Business Development & Scientific Strategy
Anavex Life Sciences
Abstract:
Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded clinical stage biopharmaceutical company dedicated to the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders. Anavex’s lead candidate, ANAVEX 2-73, is an orally available compound that restores cellular homeostasis by targeting Sigma-1 and muscarinic receptors. ANAVEX 2-73, has demonstrated good safety, bioavailability, and tolerability in Phase 1 and Phase 2 clinical trials. In addition, data from an ongoing Phase 2a clinical trial in Alzheimer’s Disease demonstrates dose dependent cognitive improvements. The compound also exhibits anticonvulsant, anti-amnesic, neuroprotective and anti-depressant properties in animal models, indicating its potential to treat a broad range of CNS disorders.
ANAVEX 2-73 significantly improves multiple behavioral phenotypes in the Rett Syndrome mouse model in a dose-related manner. Based on these data, Anavex Life Sciences will start a U.S. multicenter Phase 2 clinical trial of ANAVEX 2-73 for the treatment of Rett Syndrome with the support of Rettsyndrome.org.
The Michael J. Fox Foundation for Parkinson’s Research awarded Anavex Life Sciences a research grant to develop ANAVEX 2-73 for the treatment of Parkinson’s Disease. Ongoing preclinical research in this therapeutic area demonstrates that ANAVEX 2-73 ameliorates motor deficits in spontaneous rotational activity and forelimb use asymmetry, and exerts significant neurorestorative effects on the damaged nigrostriatal dopamine system.
The scientific rationale, preclinical data, and clinical development path of ANAVEX 2-73 as a novel treatment strategy for Rett Syndrome, Parkinson’s Disease, and Multiple Sclerosis will be discussed in more detail. This presentation will explore the links between preclinical findings and clinical trial development trajectory in our ongoing translational research efforts.
(So imo, since this is a partership/deal conference,MJFF for Parkinsons trial and Rett Organzation for Rett trial, even to speak about MS has me wondering if they have a MS deal. Thoughts?)
BIIB and other BPs did you read this Information yet ??
ATTENTION: Look who is working with Anavex 2-73:
Veronica Francardo, PhD
Assistant Professor, Department of Experimental Medical Science BMC F11 at Lund University
Location: Lund, Sweden
Veronica Francardo received her undergraduate training at the University of Trieste, Italy, where she graduated in Medical Biotechnologies. Since 2007, Veronica is a researcher at Lund University, Sweden, where she obtained her PhD degree in Neurobiology under the supervision of Prof Angela Cenci-Nilsson. Veronica Francardo is currently Assistant Professor in the group of Prof. Angela Cenci-Nilsson and carries out pre-clinical research on animal models of Parkinson’s disease and post-mortem human brain tissue. The main interest of her work is to test and develop potential new therapies for Parkinson’s disease and related disorders.
Sept 11th CNS Conference: ANAVEX 2-73, a Sigma-1 Receptor Agonist, Targeting Neurodegenerative and Neurodevelopmental Diseases
Daniel Klamer Daniel Klamer
Vice President, Business Development & Scientific Strategy
Anavex Life Sciences
Abstract:
Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded clinical stage biopharmaceutical company dedicated to the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders. Anavex’s lead candidate, ANAVEX 2-73, is an orally available compound that restores cellular homeostasis by targeting Sigma-1 and muscarinic receptors. ANAVEX 2-73, has demonstrated good safety, bioavailability, and tolerability in Phase 1 and Phase 2 clinical trials. In addition, data from an ongoing Phase 2a clinical trial in Alzheimer’s Disease demonstrates dose dependent cognitive improvements. The compound also exhibits anticonvulsant, anti-amnesic, neuroprotective and anti-depressant properties in animal models, indicating its potential to treat a broad range of CNS disorders.
ANAVEX 2-73 significantly improves multiple behavioral phenotypes in the Rett Syndrome mouse model in a dose-related manner. Based on these data, Anavex Life Sciences will start a U.S. multicenter Phase 2 clinical trial of ANAVEX 2-73 for the treatment of Rett Syndrome with the support of Rettsyndrome.org.
The Michael J. Fox Foundation for Parkinson’s Research awarded Anavex Life Sciences a research grant to develop ANAVEX 2-73 for the treatment of Parkinson’s Disease. Ongoing preclinical research in this therapeutic area demonstrates that ANAVEX 2-73 ameliorates motor deficits in spontaneous rotational activity and forelimb use asymmetry, and exerts significant neurorestorative effects on the damaged nigrostriatal dopamine system.
The scientific rationale, preclinical data, and clinical development path of ANAVEX 2-73 as a novel treatment strategy for Rett Syndrome, Parkinson’s Disease, and Multiple Sclerosis will be discussed in more detail. This presentation will explore the links between preclinical findings and clinical trial development trajectory in our ongoing translational research efforts.
(So imo, since this is a partership/deal conference,MJFF for Parkinsons trial and Rett Organzation for Rett trial, even to speak about MS has me wondering if they have a MS deal. Thoughts?)
Sept 11th CNS Conference: ANAVEX 2-73, a Sigma-1 Receptor Agonist, Targeting Neurodegenerative and Neurodevelopmental Diseases
Daniel Klamer Daniel Klamer
Vice President, Business Development & Scientific Strategy
Anavex Life Sciences
Abstract:
Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded clinical stage biopharmaceutical company dedicated to the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders. Anavex’s lead candidate, ANAVEX 2-73, is an orally available compound that restores cellular homeostasis by targeting Sigma-1 and muscarinic receptors. ANAVEX 2-73, has demonstrated good safety, bioavailability, and tolerability in Phase 1 and Phase 2 clinical trials. In addition, data from an ongoing Phase 2a clinical trial in Alzheimer’s Disease demonstrates dose dependent cognitive improvements. The compound also exhibits anticonvulsant, anti-amnesic, neuroprotective and anti-depressant properties in animal models, indicating its potential to treat a broad range of CNS disorders.
ANAVEX 2-73 significantly improves multiple behavioral phenotypes in the Rett Syndrome mouse model in a dose-related manner. Based on these data, Anavex Life Sciences will start a U.S. multicenter Phase 2 clinical trial of ANAVEX 2-73 for the treatment of Rett Syndrome with the support of Rettsyndrome.org.
The Michael J. Fox Foundation for Parkinson’s Research awarded Anavex Life Sciences a research grant to develop ANAVEX 2-73 for the treatment of Parkinson’s Disease. Ongoing preclinical research in this therapeutic area demonstrates that ANAVEX 2-73 ameliorates motor deficits in spontaneous rotational activity and forelimb use asymmetry, and exerts significant neurorestorative effects on the damaged nigrostriatal dopamine system.
The scientific rationale, preclinical data, and clinical development path of ANAVEX 2-73 as a novel treatment strategy for Rett Syndrome, Parkinson’s Disease, and Multiple Sclerosis will be discussed in more detail. This presentation will explore the links between preclinical findings and clinical trial development trajectory in our ongoing translational research efforts.
(So imo, since this is a partership/deal conference,MJFF for Parkinsons trial and Rett Organzation for Rett trial, even to speak about MS has me wondering if they have a MS deal. Thoughts?)
Sept 11th CNS Conference: ANAVEX 2-73, a Sigma-1 Receptor Agonist, Targeting Neurodegenerative and Neurodevelopmental Diseases
Daniel Klamer Daniel Klamer
Vice President, Business Development & Scientific Strategy
Anavex Life Sciences
Abstract:
Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded clinical stage biopharmaceutical company dedicated to the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders. Anavex’s lead candidate, ANAVEX 2-73, is an orally available compound that restores cellular homeostasis by targeting Sigma-1 and muscarinic receptors. ANAVEX 2-73, has demonstrated good safety, bioavailability, and tolerability in Phase 1 and Phase 2 clinical trials. In addition, data from an ongoing Phase 2a clinical trial in Alzheimer’s Disease demonstrates dose dependent cognitive improvements. The compound also exhibits anticonvulsant, anti-amnesic, neuroprotective and anti-depressant properties in animal models, indicating its potential to treat a broad range of CNS disorders.
ANAVEX 2-73 significantly improves multiple behavioral phenotypes in the Rett Syndrome mouse model in a dose-related manner. Based on these data, Anavex Life Sciences will start a U.S. multicenter Phase 2 clinical trial of ANAVEX 2-73 for the treatment of Rett Syndrome with the support of Rettsyndrome.org.
The Michael J. Fox Foundation for Parkinson’s Research awarded Anavex Life Sciences a research grant to develop ANAVEX 2-73 for the treatment of Parkinson’s Disease. Ongoing preclinical research in this therapeutic area demonstrates that ANAVEX 2-73 ameliorates motor deficits in spontaneous rotational activity and forelimb use asymmetry, and exerts significant neurorestorative effects on the damaged nigrostriatal dopamine system.
The scientific rationale, preclinical data, and clinical development path of ANAVEX 2-73 as a novel treatment strategy for Rett Syndrome, Parkinson’s Disease, and Multiple Sclerosis will be discussed in more detail. This presentation will explore the links between preclinical findings and clinical trial development trajectory in our ongoing translational research efforts.
(So imo, since this is a partership/deal conference,MJFF for Parkinsons trial and Rett Organzation for Rett trial, even to speak about MS has me wondering if they have a MS deal. Thoughts?)
Sept 11th CNS Conference: ANAVEX 2-73, a Sigma-1 Receptor Agonist, Targeting Neurodegenerative and Neurodevelopmental Diseases
Daniel Klamer Daniel Klamer
Vice President, Business Development & Scientific Strategy
Anavex Life Sciences
Abstract:
Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded clinical stage biopharmaceutical company dedicated to the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders. Anavex’s lead candidate, ANAVEX 2-73, is an orally available compound that restores cellular homeostasis by targeting Sigma-1 and muscarinic receptors. ANAVEX 2-73, has demonstrated good safety, bioavailability, and tolerability in Phase 1 and Phase 2 clinical trials. In addition, data from an ongoing Phase 2a clinical trial in Alzheimer’s Disease demonstrates dose dependent cognitive improvements. The compound also exhibits anticonvulsant, anti-amnesic, neuroprotective and anti-depressant properties in animal models, indicating its potential to treat a broad range of CNS disorders.
ANAVEX 2-73 significantly improves multiple behavioral phenotypes in the Rett Syndrome mouse model in a dose-related manner. Based on these data, Anavex Life Sciences will start a U.S. multicenter Phase 2 clinical trial of ANAVEX 2-73 for the treatment of Rett Syndrome with the support of Rettsyndrome.org.
The Michael J. Fox Foundation for Parkinson’s Research awarded Anavex Life Sciences a research grant to develop ANAVEX 2-73 for the treatment of Parkinson’s Disease. Ongoing preclinical research in this therapeutic area demonstrates that ANAVEX 2-73 ameliorates motor deficits in spontaneous rotational activity and forelimb use asymmetry, and exerts significant neurorestorative effects on the damaged nigrostriatal dopamine system.
The scientific rationale, preclinical data, and clinical development path of ANAVEX 2-73 as a novel treatment strategy for Rett Syndrome, Parkinson’s Disease, and Multiple Sclerosis will be discussed in more detail. This presentation will explore the links between preclinical findings and clinical trial development trajectory in our ongoing translational research efforts.
(So imo, since this is a partership/deal conference,MJFF for Parkinsons trial and Rett Organzation for Rett trial, even to speak about MS has me wondering if they have a MS deal. Thoughts?)
I saw no previous abstract and this abstract contains no verbiage " has the potential too". I think you are missing the boat here. This is a CNS partnering Conference. AVXL is partnering with Rett Organization with Rett trial. MJFF on Parkinson. So if they are even willing to discuss MS at this CNS Partnering and Deal Conference, I am asking myself who is their partner or deal maker in MS????
Maybe because the conference is entitled CNS Partnering and Deal Making. We already know they have the Rett organization for partnering with Rett trials, and MJF Foundation for Parkinson, so who is partnering with us on MS??? Mmm.
Alzheimers won't be discussed since we have no official partner yet. YET being the key word.
Sept 11th CNS Conference: ANAVEX 2-73, a Sigma-1 Receptor Agonist, Targeting Neurodegenerative and Neurodevelopmental Diseases
Daniel Klamer Daniel Klamer
Vice President, Business Development & Scientific Strategy
Anavex Life Sciences
Abstract:
Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded clinical stage biopharmaceutical company dedicated to the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders. Anavex’s lead candidate, ANAVEX 2-73, is an orally available compound that restores cellular homeostasis by targeting Sigma-1 and muscarinic receptors. ANAVEX 2-73, has demonstrated good safety, bioavailability, and tolerability in Phase 1 and Phase 2 clinical trials. In addition, data from an ongoing Phase 2a clinical trial in Alzheimer’s Disease demonstrates dose dependent cognitive improvements. The compound also exhibits anticonvulsant, anti-amnesic, neuroprotective and anti-depressant properties in animal models, indicating its potential to treat a broad range of CNS disorders.
ANAVEX 2-73 significantly improves multiple behavioral phenotypes in the Rett Syndrome mouse model in a dose-related manner. Based on these data, Anavex Life Sciences will start a U.S. multicenter Phase 2 clinical trial of ANAVEX 2-73 for the treatment of Rett Syndrome with the support of Rettsyndrome.org.
The Michael J. Fox Foundation for Parkinson’s Research awarded Anavex Life Sciences a research grant to develop ANAVEX 2-73 for the treatment of Parkinson’s Disease. Ongoing preclinical research in this therapeutic area demonstrates that ANAVEX 2-73 ameliorates motor deficits in spontaneous rotational activity and forelimb use asymmetry, and exerts significant neurorestorative effects on the damaged nigrostriatal dopamine system.
The scientific rationale, preclinical data, and clinical development path of ANAVEX 2-73 as a novel treatment strategy for Rett Syndrome, Parkinson’s Disease, and Multiple Sclerosis will be discussed in more detail. This presentation will explore the links between preclinical findings and clinical trial development trajectory in our ongoing translational research efforts. (Looks like MS will be discussed and AD kept quiet..is this a quiet period hint?)
NEWS DURHAM, N.C., Aug. 17, 2017 /PRNewswire/ -- MGT Capital Investments, Inc. (OTC: MGTI) Today, MGT announced the deployment of 650 new Bitmain S9 Bitcoin mining rigs. These units are located at a new multi MegaWatt facility in central Washington state. The Company anticipates completing the installation and reaching full production within the next two weeks. The incorporation of these new mining rigs continues MGT's strategy to boost its competitive edge in this rapidly growing industry.
Stephen Schaeffer, President of MGT Crypto-Capital Strategies stated, "With the recent highs of $4,500 per bitcoin, the business of mining is as profitable as ever. I couldn't be more excited about the timing of my new appointment, and I truly believe we will build MGT into a mining powerhouse in the U. S."
The Company recently passed a milestone of having mined 1,000 bitcoins since it began operations in September 2016. Robert Ladd, Chief Executive Officer of MGT commented, "We are committed to this sector and look forward to updating stockholders on our continuing growth."
News: UPLISTING. HUGE HIRE. EXPANSION of Cryptocurrencies! MGTI will be a leader in all BLOCKCHAIN acticities in the future. Low # of shares with enormous upside. Only use speculation money.
3D, DId you really get word of mining update? It is overdue for news since May pr release estimated July for new machines. I suggest someone ask JM on twitter when we get update. I think stock flies on that news but don't blow smoke if you did not get info that a release is coming this week..wILL show whether you do your homework or not .
Blockchain is like the internet in the 90s. Is MGTI another early leader? Can John McAfee do it again?
I dont see a stock symbol BITCF,,whats the name?
My guess is a big partnership before year end.$14+
PR Newswire
DURHAM, N.C., May 22, 2017
DURHAM, N.C., May 22, 2017 /PRNewswire/ -- MGT Capital Investments, Inc. (OTC: MGTI) announced today that it has closed on financing to allow the Company to materially ramp up its Bitcoin mining operations. The financing consists of a $1.35 million 10% convertible note (convertible at $1.05 per MGTI share) issued to a single institutional investor. The note is self-amortizing with a maximum repayment of $90,000 per month. In conjunction with the note, the Company also issued the investor 1.2 million warrants with an exercise price of $1.05 per MGTI share.
The proceeds of the financing, along with Company cash reserves will allow MGT to purchase 1,000 Bitmain Antminer S9 computers and associated power supplies. Following shipment and setup (expected by early July 2017), MGT will be operating a total of 1,400 S9's with total computing power of over 18 PH/s, generating an estimated 225 Bitcoins per month with a value currently of over $450,000. Factoring in electricity, hosting and other direct operating costs, EBITDA from the Company's Bitcoin mining operations is projected at $300,000 per month, prior to note amortization.
John McAfee stated, "Today's announcement is transformational for MGT. Not only does it vastly improve our financial profile, but it positions us as the only public company in the space at a time when Bitcoin has enormous momentum."
SO WHO TWEETED JOHN TO GET AN UPDATE ON THIS?
My guess. BABA or BIDU buys YY @ 20x eps or $120
Who can tweet John M. and find out when the additional bitcoin machines will be running? May's Pr said July. I dont have a twiiter account. Let us know his reply. Thx.
Can we get an update on this News?
PR Newswire
DURHAM, N.C., May 22, 2017
DURHAM, N.C., May 22, 2017 /PRNewswire/ -- MGT Capital Investments, Inc. (OTC: MGTI) announced today that it has closed on financing to allow the Company to materially ramp up its Bitcoin mining operations. The financing consists of a $1.35 million 10% convertible note (convertible at $1.05 per MGTI share) issued to a single institutional investor. The note is self-amortizing with a maximum repayment of $90,000 per month. In conjunction with the note, the Company also issued the investor 1.2 million warrants with an exercise price of $1.05 per MGTI share.
The proceeds of the financing, along with Company cash reserves will allow MGT to purchase 1,000 Bitmain Antminer S9 computers and associated power supplies. Following shipment and setup (expected by early July 2017), MGT will be operating a total of 1,400 S9's with total computing power of over 18 PH/s, generating an estimated 225 Bitcoins per month with a value currently of over $450,000. Factoring in electricity, hosting and other direct operating costs, EBITDA from the Company's Bitcoin mining operations is projected at $300,000 per month, prior to note amortization.
John McAfee stated, "Today's announcement is transformational for MGT. Not only does it vastly improve our financial profile, but it positions us as the only public company in the space at a time when Bitcoin has enormous momentum."
HUGE earnings and Huge guidance just posted !
Buying YY huge growth and only 17x earnings compareded to BIGU, BABA, MOMO, WB high pe.
Tweet John and ask if added bitcoin machines announced in May are up and running? Let us know. I see $5+ if so.
Continuing LOW Volume selloffs, rebounds are sharp when they occur.
YY trades at only 17x earnings compared to BABA and BIDU and MOMO etc.at 40-60x
YY trades at only 17x earnings compared to BABA and BIDU and MOMO etc.
BABA trades 64x earnings. YY only 17X !!
BABA trades 64x earnings, YY only 17x !!
BIDU trades 43x earnings. YY only 17x !
With IND filed and highly likely to be accepted in less than 60 days, this 22 million market cap should rise to a 220 million market cap in a very short time. Add the amazing results in the combo drug with MRK and you can have a 2 billion MC.
Will continue to buy up until trials start. Market cap is undervalued and even 10x higher will still be undervalued. Short term holders should not be in this stock.They should be in NVDA where I bought 10x cheaper than were it trades today.
Sentinal Beta testing sent to several sites including Macys according to posts from John and Macy employee. I just googled his twitter page. Can someone tweet him and ask for updates on Bitcoin ramped up Volume?
I had my biggest winners in quiet Biotech companies. I accumulate during periods of little news like we are in now and Acquire an affordable amount of shares, I usually hope these companies get cheaper as I accumulate. My experience has been successful avoiding bios that issue tons of pr releases. This company is building from the inside and designing trials under FDA guidance. Missling states that he designed phase 2 to fail but it didn't so phase 3 is being set up to confirm the amazing results in phase 2. But I understand, its alot like Christmas morning buildup. Waiting to open the present. So ask yourself, do you get excited 6 months before Christmas morning?
Market cap and stock could rise 10x and still be at a ridiculous level for any small mid cap biotech. Currently 22 million mc, at 220 million still vey very cheap ! IND news is wonderful and stock will continue to gain momentum.